Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

Procedures to implant the WATCHMAN left atrial occlusion device had a high implant success rate and a low rate of in-hospital complications in an analysis of more than 38,000 procedures presented at ...

Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific’s Watchman FLX Pro device, the latest version of its left atrial appendage closure system, was approved by the ...

Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing a transcatheter aortic valve replacement (TAVR) at the same time as a left atrial appendage ...

Direct current cardioversion for symptomatic atrial fibrillation or flutter is feasible and safe in patients implanted with the Watchman left atrial appendage (LAA) occlusion device, even in the ...

The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...

A small series provides provocative new data on the safety of performing direct current cardioversion (DCCV) without oral anticoagulation in high-risk patients with a Watchman left atrial appendage ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Boston Scientific has obtained an FDA green light for the latest version of its Watchman heart implant, designed to help lower the risk of stroke in patients with atrial fibrillation. Compared to its ...

NATICK, Mass., Boston Scientific Corporation reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left Atrial Appendage (LAA) Closure device was ...